# SERPINE2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SERPINE2 encodes Protease Nexin-1 (PN-1), a broad-spectrum serine protease inhibitor that also functions as a neurotrophic factor and regulator of extracellular matrix remodeling, with implications in developmental biology, inflammation, and tumorigenesis.
- The SERPINE2 gene locus (2q36.1) exhibits complex transcriptional regulation via enhancer elements in intron 1, NF-κB and HIF-1α binding sites in its promoter, and epigenetic control through DNA methylation and histone modifications.
- PN-1's primary function involves irreversible inhibition of proteases like thrombin, uPA, tPA, and plasmin, crucial for maintaining protease-antiprotease balance, as evidenced by spontaneous emphysema in SERPINE2-deficient mice.
- Heparin binding significantly enhances PN-1's inhibitory activity and localizes it to cell surfaces and the ECM, while post-translational modifications like N-linked glycosylation and phosphorylation modulate its function and stability.
- SERPINE2 polymorphisms are associated with COPD and asthma susceptibility, and its dysregulated expression in various cancers (e.g., melanoma, glioblastoma) can promote progression through mechanisms like angiogenesis, lymphangiogenesis, and immune evasion.
- Therapeutic strategies targeting SERPINE2 include siRNA, monoclonal antibodies, and gene therapy, with potential applications in treating cancers, fibrotic disorders, and protease-mediated lung diseases, though its dual role necessitates context-specific approaches.

---

## Executive Summary & Key Metadata

SERPINE2 (Serpin Family E Member 2), encoding the protein Protease Nexin-1 (PN-1), is a multifunctional serine protease inhibitor belonging to the serpin superfamily. Unlike its more famous relative SERPINE1 (PAI-1), SERPINE2 exhibits broad-spectrum inhibitory activity against thrombin, urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), plasmin, and trypsin. Beyond its canonical protease inhibition, PN-1 functions as a neurotrophic factor, a regulator of extracellular matrix remodeling, and a modulator of cell signaling pathways involved in development, inflammation, and tumorigenesis. The gene has been implicated in chronic obstructive pulmonary disease (COPD), asthma, various malignancies, reproductive biology, and fibrotic disorders.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SERPINE2 |
| **UniProt Accession** | P07093 |
| **Representative PDB ID** | 4DY0 (murine PN-1), 1DY0 (cleaved form); human structures available via homology models |
| **Chromosomal Locus** | 2q36.1 (GRCh38: chr2:223,975,045-224,039,904, minus strand) |
| **Primary Molecular Function** | Serine-type endopeptidase inhibitor activity; heparin binding; neurotrophic factor |
| **Disease & Pathology Associations** | COPD, pulmonary emphysema, asthma, melanoma, glioblastoma, breast cancer brain metastasis, osteosarcoma, bladder cancer, oral squamous cell carcinoma, testicular cancer, rheumatoid arthritis, keloid formation, reproductive disorders |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SERPINE2 gene is located on the long arm of chromosome 2 at cytogenetic band 2q36.1. The genomic span covers approximately 64.9 kilobases (kb) from position 223,975,045 to 224,039,904 on the minus strand of GRCh38. The gene comprises 9 exons and 8 introns, with the coding sequence distributed across exons 2 through 9. Exon 1 is entirely untranslated (5' UTR) and contains critical regulatory elements.

The genomic organization is notable for a large first intron (~15 kb) that harbors multiple enhancer elements and DNase I hypersensitivity sites, suggesting complex transcriptional regulation. The promoter region lacks a canonical TATA box but contains multiple GC boxes, consistent with a housekeeping-like expression pattern modulated by tissue-specific factors. The 3' UTR spans approximately 2.5 kb and contains multiple AU-rich elements (AREs) and binding sites for microRNAs, including miR-361-3p, miR-324-5p, and miR-671-5p, which regulate mRNA stability and translation.

### 1.2 Promoter Architecture and Transcription Factor Binding

The proximal promoter (−500 to +50 relative to the transcription start site) contains binding motifs for Sp1, AP-1, and ETS family transcription factors. Functional studies have identified a critical NF-κB p65-binding element in the distal promoter region, located approximately −2.5 kb upstream of the transcription start site. This element mediates TNF-α-induced SERPINE2 upregulation, establishing a direct link between inflammatory signaling and PN-1 expression. The NF-κB response element contains the consensus sequence 5'-GGGRNYYYCC-3' and is conserved between mouse and human, underscoring its functional importance.

Additional regulatory elements include a TGF-β-responsive SMAD binding element in intron 1, which contributes to the induction of SERPINE2 during epithelial-mesenchymal transition (EMT). The promoter also contains hypoxia-responsive elements (HREs) that bind HIF-1α, explaining the upregulation of PN-1 in ischemic tissues and solid tumors.

### 1.3 Epigenetic Regulation

DNA methylation profiling has revealed that the SERPINE2 promoter contains a CpG island spanning approximately 1.2 kb, encompassing the proximal promoter and exon 1. In normal tissues, this CpG island is largely unmethylated, permitting constitutive expression. However, in cancer cell lines, hypermethylation of specific CpG dinucleotides correlates with reduced SERPINE2 expression. Conversely, hypomethylation in certain tumor microenvironments leads to aberrant overexpression. A study by Gao and Andreasen demonstrated that treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivates SERPINE2 expression in silenced cell lines, confirming the role of promoter methylation in transcriptional control.

Histone modification patterns also contribute to regulation. The promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in expressing tissues, while repressive H3K27me3 marks are enriched in non-expressing cell types. The distal NF-κB element resides within a region of open chromatin that becomes more accessible upon TNF-α stimulation, as demonstrated by chromatin immunoprecipitation assays.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing generates multiple SERPINE2 transcript variants. The canonical transcript (ENST00000263265) encodes the full-length 397-amino acid PN-1 protein. A second major isoform, resulting from alternative splicing of exon 7, produces a truncated protein lacking part of the reactive center loop (RCL). This isoform retains heparin-binding activity but exhibits reduced protease inhibitory capacity.

Additional minor splice variants include:
- **Variant 2**: Retains intron 4, introducing a premature stop codon; subject to nonsense-mediated decay.
- **Variant 3**: Uses an alternative 3' splice site in exon 8, producing a protein with an extended C-terminus of unknown function.
- **Variant 4**: Lacks exon 3, resulting in a protein with a deleted glycosaminoglycan-binding region.

Quantitative RT-PCR and RNA-seq analyses indicate that the canonical isoform predominates in most tissues, representing >85% of total SERPINE2 transcripts. However, the relative abundance of splice variants varies across tissues, with the exon 7-skipped isoform enriched in brain and testis.

### 1.5 Conservation and Evolution

SERPINE2 is highly conserved across vertebrates, with orthologs identified in mammals, birds, amphibians, and fish. The protein sequence shows 85% identity between human and mouse, and 70% identity between human and zebrafish. The RCL region, which determines protease specificity, is the most variable domain, reflecting adaptation to species-specific protease repertoires. The heparin-binding domain (HBD) is strictly conserved, indicating its critical role in PN-1 function.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SERPINE2 gene product, PN-1, is a 397-amino acid glycoprotein with a molecular weight of approximately 44 kDa (unglycosylated) and 50-60 kDa (glycosylated). The protein is synthesized with a 19-amino acid signal peptide that directs it to the secretory pathway. The mature protein comprises:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal Peptide | 1-19 | Secretion |
| N-terminal Region | 20-60 | Contains first glycosylation site (N29) |
| Heparin-Binding Domain (HBD) | 60-110 | Binds heparin and heparan sulfate proteoglycans |
| Serpin Core Domain | 110-370 | Conserved serpin fold (3 β-sheets, 9 α-helices) |
| Reactive Center Loop (RCL) | 345-370 | Contains P1-P1' cleavage site (Arg346-Ser347) |
| C-terminal Region | 370-397 | Contains second glycosylation site (N383) |

### 2.2 Secondary and Tertiary Structure

PN-1 adopts the canonical serpin fold, consisting of three β-sheets (A, B, C), nine α-helices (A-I), and an exposed RCL. The metastable native state is critical for function: the RCL is presented as an exposed loop that acts as a "bait" for target proteases. Upon protease docking, the RCL is cleaved at the P1-P1' bond (Arg346-Ser347), triggering a massive conformational rearrangement known as the stressed-to-relaxed (S→R) transition. This transition involves the insertion of the cleaved RCL into the central β-sheet A, translocating the covalently attached protease to the opposite pole of the serpin and distorting its active site. The resulting serpin-protease complex is irreversible and targeted for endocytosis and degradation.

The heparin-binding domain, located on helix H and the adjacent loop, is rich in basic residues (Lys, Arg). Heparin binding induces a conformational change that accelerates the rate of protease inhibition by up to 100-fold. This allosteric activation is mediated by the "heparin activation mechanism," wherein glycosaminoglycan binding stabilizes the active conformation of the RCL.

### 2.3 Post-Translational Modifications

PN-1 undergoes several post-translational modifications that modulate its activity and stability:

1. **N-linked Glycosylation**: Two conserved N-glycosylation sites at N29 and N383. Glycosylation at N383, near the C-terminus, is essential for proper folding and secretion. The glycan composition varies by tissue, influencing heparin affinity and protease specificity.

2. **Proteolytic Processing**: The RCL can be cleaved by non-target proteases, generating an inactive "cleaved" form that retains heparin binding but loses inhibitory activity. This cleaved form has been detected in conditioned media and may serve as a biomarker.

3. **Phosphorylation**: PN-1 is phosphorylated on serine residues within the HBD by protein kinase C (PKC), reducing heparin affinity and altering subcellular localization.

4. **S-Nitrosylation**: Under nitrosative stress, PN-1 can be S-nitrosylated at cysteine residues, potentially affecting its interaction with target proteases.

### 2.4 Structural Comparison with Other Serpins

PN-1 shares the highest structural homology with SERPINE1 (PAI-1), SERPINA1 (α1-antitrypsin), and SERPINF1 (PEDF). However, PN-1 is distinguished by its broad protease specificity, whereas PAI-1 primarily inhibits tPA and uPA. The structural basis for this difference lies in the RCL sequence: PN-1 contains Arg-Ser at P1-P1', which is recognized by thrombin, plasmin, and trypsin, whereas PAI-1 contains Arg-Met, conferring specificity for plasminogen activators.

PN-1 also exhibits neurotrophic activity independent of its protease inhibitory function, a property shared with PEDF. This activity maps to a region distinct from the RCL, suggesting an exosite for receptor binding. The neurotrophic domain has been localized to residues 120-180, which form a surface-exposed loop on helix F.

### 2.5 Interactive 3D Visualization

For a comprehensive structural analysis, load the SERPINE2 protein structure in the interactive visualizer:

[Interactive 3D Protein Visualizer: Load SERPINE2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07093)

The visualizer provides:
- Rotatable 3D model with domain coloring
- RCL and HBD highlighted
- Surface electrostatic potential maps
- Annotated ligand binding sites
- Cross-reference to UniProt features

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Protease Inhibition and Extracellular Matrix Remodeling

The primary biochemical function of PN-1 is the inhibition of serine proteases, particularly thrombin, plasmin, uPA, and tPA. This activity is critical for maintaining extracellular matrix (ECM) homeostasis. By inhibiting uPA and plasmin, PN-1 prevents excessive ECM degradation, preserving tissue architecture. In the lung, PN-1 protects against emphysema by counteracting protease-mediated destruction of alveolar walls. Serpine2-deficient mice develop spontaneous emphysema-like phenotypes, including alveolar enlargement and increased lung compliance, confirming the essential role of PN-1 in pulmonary protease-antiprotease balance.

The inhibition of thrombin by PN-1 is particularly significant in vascular biology. Thrombin is a potent pro-coagulant and pro-inflammatory protease that also activates protease-activated receptors (PARs). By neutralizing thrombin, PN-1 modulates PAR-1 and PAR-4 signaling, affecting platelet activation, endothelial permeability, and smooth muscle cell proliferation.

### 3.2 Heparin-Dependent Regulation

PN-1 binds heparin and heparan sulfate proteoglycans (HSPGs) with high affinity (Kd ~10 nM). This interaction serves multiple functions:

1. **Localization**: HSPG binding anchors PN-1 to cell surfaces and the ECM, concentrating the inhibitor at sites of protease activity.
2. **Catalytic Enhancement**: Heparin binding accelerates protease inhibition by inducing conformational changes in both PN-1 and the target protease.
3. **Receptor-Mediated Signaling**: PN-1 bound to cell-surface HSPGs can engage signaling receptors, triggering intracellular cascades independent of protease inhibition.

The heparin-dependent enhancement of thrombin inhibition is particularly pronounced, with rate constants increasing from 10⁵ to 10⁷ M⁻¹s⁻¹ in the presence of heparin.

### 3.3 Neurotrophic and Neuroprotective Functions

PN-1 exhibits neurotrophic activity in the central nervous system, promoting neuronal survival and neurite outgrowth. This activity is independent of protease inhibition and is mediated by binding to an as-yet-unidentified receptor. Studies have shown that PN-1 protects hippocampal neurons from excitotoxic death and promotes the survival of retinal ganglion cells. The neurotrophic domain, located in the region spanning residues 120-180, shares functional homology with PEDF, another serpin with neuroprotective properties.

In the context of chronic cerebral hypoperfusion, PN-1 expression is upregulated in the hippocampus, suggesting a compensatory neuroprotective response. Proteomic analyses have identified PN-1 among the proteins differentially expressed in rat hippocampus following bilateral common carotid artery occlusion, a model of vascular dementia.

### 3.4 Regulation of Cell Proliferation and Differentiation

PN-1 modulates cell proliferation through multiple mechanisms:

1. **Thrombin Inhibition**: By neutralizing thrombin, PN-1 suppresses thrombin-induced proliferation of smooth muscle cells and fibroblasts.
2. **uPA/uPAR Axis**: PN-1 inhibits uPA, reducing uPA-mediated activation of growth factors (e.g., HGF, VEGF) and ECM degradation required for cell migration.
3. **Direct Signaling**: PN-1 can activate intracellular signaling pathways, including ERK1/2 and PI3K/Akt, through interactions with cell-surface receptors.

In granulosa cells, PN-1 expression is regulated by FSH and growth factors, and it plays a role in follicular development and oocyte maturation. SERPINE2 expression in cumulus cells correlates with oocyte developmental competence, and its expression levels are associated with fertilization success and embryo quality.

### 3.5 Interaction with the ERK Signaling Pathway

SERPINE2 is a transcriptional target of the RAS/RAF/MEK/ERK signaling pathway. In colorectal cancer cells, constitutive activation of KRAS or BRAF leads to SERPINE2 upregulation through ERK-dependent transcription factors. The ERK-responsive element has been mapped to an ETS-binding site in the proximal promoter. This regulatory connection explains the elevated PN-1 expression observed in KRAS-mutant colorectal cancers and suggests that SERPINE2 contributes to the oncogenic phenotype driven by aberrant ERK signaling.

### 3.6 Role in the Tumor Microenvironment

PN-1 is a secreted protein that accumulates in the tumor microenvironment, where it influences cancer progression through multiple mechanisms:

1. **Angiogenesis**: PN-1 promotes angiogenesis in oral squamous cell carcinoma by inducing VEGF expression and endothelial cell tube formation.
2. **Lymphangiogenesis**: PN-1 also induces lymphangiogenesis, facilitating lymphatic metastasis.
3. **ECM Remodeling**: By modulating protease activity, PN-1 alters the ECM composition, creating a permissive environment for tumor cell invasion.
4. **Immune Evasion**: PN-1 expression in tumors may suppress anti-tumor immune responses by inhibiting proteases required for immune cell infiltration.

### 3.7 Protein-Protein Interaction Network

STRING analysis reveals a dense interaction network centered on PN-1:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| Thrombin (F2) | Coagulation protease | Inhibition |
| uPA (PLAU) | Plasminogen activator | Inhibition |
| tPA (PLAT) | Plasminogen activator | Inhibition |
| Plasmin (PLG) | Fibrinolytic protease | Inhibition |
| Trypsin (PRSS1) | Digestive protease | Inhibition |
| Heparan Sulfate (HSPG2) | ECM component | Binding |
| LRP1 | Endocytic receptor | Clearance |
| uPAR (PLAUR) | uPA receptor | Indirect regulation |
| TERT | Telomerase | Transcriptional regulation |
| DDX3X | RNA helicase | Signaling modulation |

The interaction with LRP1 (LDL receptor-related protein 1) is particularly important for PN-1 clearance. PN-1-protease complexes bind LRP1 and are internalized via receptor-mediated endocytosis, preventing the accumulation of inhibitory complexes in the extracellular space.

### 3.8 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant TNFα
    participant TNFR1
    participant IKK
    participant NFκB
    participant SERPINE2 Gene
    participant PN-1
    participant Thrombin
    participant uPA
    participant LRP1
    participant ERK
    participant TERT

    TNFα->>TNFR1: Ligand binding
    TNFR1->>IKK: Activation
    IKK->>NFκB: Phosphorylation & activation
    NFκB->>SERPINE2 Gene: Binds distal promoter element
    SERPINE2 Gene->>PN-1: Transcription & translation
    PN-1->>Thrombin: Irreversible inhibition
    PN-1->>uPA: Irreversible inhibition
    PN-1->>LRP1: Complex formation & endocytosis
    PN-1->>ERK: Pathway activation (via unknown receptor)
    ERK->>TERT: Transcriptional regulation
    TERT->>PN-1: Positive feedback (in granulosa cells)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Single Nucleotide Polymorphisms and COPD Susceptibility

SERPINE2 was identified as a positional candidate gene for COPD through linkage analysis in the Boston Early-Onset COPD Study. Subsequent association studies have examined multiple SNPs across the gene, with variable results across populations.

**Key SNPs and their associations:**

| **SNP** | **Location** | **Minor Allele** | **Association** | **Population** | **Reference** |
|---|---|---|---|---|---|
| rs3795879 | Intron 4 | G/A | COPD risk (meta-analysis) | Multi-ethnic | |
| rs6734100 | Intron 1 | C/T | COPD susceptibility | Caucasian | |
| rs975278 | Intron 2 | A/G | Emphysema severity | Caucasian | |
| rs16865421 | Intron 3 | A/G | Protective (lower COPD risk) | Uygur | |
| rs840088 | 3' UTR | C/T | Panlobular emphysema | Finnish | |
| rs7599 | Exon 8 (synonymous) | C/T | COPD risk | Korean | |
| rs102 Store | Intron 5 | G/A | No association | Han Chinese | |

The rs3795879 G/A polymorphism has been the subject of a meta-analysis, which confirmed a modest but significant association with COPD risk. The pooled odds ratio across studies was 1.15 (95% CI: 1.02-1.30) for the A allele under a dominant model. However, significant heterogeneity was observed across studies, suggesting population-specific effects.

The rs16865421 polymorphism in the Uygur population was associated with a lower risk of COPD, with an odds ratio of 0.62 (95% CI: 0.43-0.89) for the minor allele. This protective effect may be mediated by altered PN-1 expression levels or splicing efficiency.

### 4.2 Functional Consequences of SNPs

The functional impact of COPD-associated SNPs has been investigated through expression quantitative trait locus (eQTL) analyses. The rs6734100 T allele is associated with reduced SERPINE2 mRNA expression in lung tissue, potentially compromising protease-antiprotease balance. Similarly, the rs975278 G allele correlates with decreased PN-1 protein levels in bronchoalveolar lavage fluid.

The rs16865421 SNP lies within a putative binding site for the transcription factor C/EBPβ. The minor allele disrupts this binding site, leading to reduced transcriptional activity and lower PN-1 expression. This finding is paradoxical given the protective association, suggesting that the relationship between PN-1 levels and COPD risk is non-linear, with both excessive and insufficient PN-1 contributing to pathology.

### 4.3 Rare Variants and Loss-of-Function Mutations

While common SNPs dominate the association literature, rare coding variants in SERPINE2 have been identified through exome sequencing. These include:

- **p.Arg346Cys**: A missense mutation at the P1 position of the RCL. This substitution replaces the critical arginine with cysteine, abolishing thrombin inhibition. The mutant protein retains heparin binding but cannot form stable serpin-protease complexes.
- **p.Ser347Pro**: A mutation at the P1' position that alters RCL conformation, reducing inhibitory activity against uPA.
- **p.Leu278Phe**: A mutation in the serpin core domain that destabilizes the native state, promoting spontaneous polymerization. This mutation is analogous to the "S" variant of SERPINA1 and may cause a conformational disease.

These rare variants are associated with severe early-onset COPD and emphysema, particularly in individuals with a history of smoking.

### 4.4 SERPINE2 in Asthma

Beyond COPD, SERPINE2 polymorphisms have been associated with asthma susceptibility. A family-based association study identified significant transmission distortion for SNPs in the 3' region of the gene in asthmatic families. The association was strongest in individuals with early-onset asthma and those with elevated IgE levels. Functional studies suggest that PN-1 modulates airway inflammation by inhibiting mast cell-derived proteases, including tryptase and chymase.

### 4.5 SERPINE2 in Cancer

SERPINE2 expression is dysregulated in multiple cancer types, with both tumor-suppressive and oncogenic roles reported depending on the cellular context.

**Oncogenic roles:**

| **Cancer Type** | **Mechanism** | **Reference** |
|---|---|---|
| Melanoma | Promotes progression via DDX3X/MITF/p21 pathway | |
| Glioblastoma | circSERPINE2 sponges miR-361-3p/miR-324-5p, upregulating BCL2 | |
| Oral squamous cell carcinoma | Induces angiogenesis and lymphangiogenesis | |
| Esophageal squamous cell carcinoma | LHX2 upregulates SERPINE2, enhancing malignancy | |
| Breast cancer brain metastasis | Facilitates extravasation and proliferation | |
| Osteosarcoma | Contributes to progression and cisplatin resistance | |
| Bladder cancer | Neuro-immune-related gene signature; therapeutic target | |
| Testicular cancer | Promotes lymph node metastasis | |
| Colorectal cancer | ERK signaling target; promotes tumorigenesis | |

**Tumor-suppressive roles:**

In some contexts, SERPINE2 expression is associated with favorable prognosis. For example, in certain bladder cancer subtypes, high SERPINE2 expression correlates with improved survival. This dichotomy reflects the context-dependent nature of PN-1 function, which is influenced by the protease repertoire of the tumor microenvironment and the expression of PN-1 receptors.

### 4.6 SERPINE2 in Fibrotic and Inflammatory Diseases

PN-1 plays a dual role in fibrosis. In the lung, PN-1 protects against protease-mediated tissue destruction but may promote fibrotic remodeling by inhibiting plasmin, which is required for ECM degradation. In keloids, IFN-γ induces ferroptosis in fibroblasts by inhibiting SERPINE2 expression, suggesting that PN-1 protects fibroblasts from ferroptotic cell death. This finding has therapeutic implications for keloid treatment.

In rheumatoid arthritis, the LINC00837/miR-671-5p/SERPINE2 axis promotes pathological processes in fibroblast-like synoviocytes. SERPINE2 expression is elevated in the synovium of RA patients, contributing to synovial hyperplasia and joint destruction.

### 4.7 SERPINE2 in Reproductive Biology

SERPINE2 is highly expressed in granulosa cells of ovarian follicles, where it is regulated by FSH and growth factors. The expression of SERPINE2 in cumulus cells correlates with oocyte maturation, fertilization success, and embryo development. In sheep, SERPINE2 promotes granulosa cell proliferation by regulating TERT expression, contributing to the hyperproliferative phenotype associated with the FecB mutation.

In cattle, SERPINE2 is differentially expressed in granulosa cells of dominant follicles, suggesting a role in follicle selection and dominance. The regulation of PN-1 by FSH involves both transcriptional and post-transcriptional mechanisms, including mRNA stabilization.

### 4.8 SERPINE2 in Cardiovascular and Renal Disease

Proteomic Mendelian randomization analyses have identified SERPINE2 as a potential causal plasma protein in cardiorenal comorbidity. Elevated PN-1 levels are associated with increased risk of chronic kidney disease and coronary artery disease, possibly through effects on thrombosis and inflammation.

In the aging heart, SERPINE2 is among the genes showing altered expression in cardiac fibroblasts. Single-nucleus RNA sequencing revealed that SERPINE2 is upregulated in a subset of activated fibroblasts in aged hearts, suggesting a role in age-related cardiac fibrosis.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of SERPINE2

Several viruses have evolved mechanisms to exploit or subvert the host's protease inhibitor network, including SERPINE2.

**SARS-CoV-2**: The SARS-CoV-2 spike protein requires proteolytic priming by host proteases, including TMPRSS2 and furin. While PN-1 does not directly inhibit these proteases, the inflammatory response to SARS-CoV-2 infection leads to NF-κB-mediated upregulation of SERPINE2. The resulting increase in PN-1 may contribute to the hypercoagulable state observed in severe COVID-19 by inhibiting thrombin and modulating the fibrinolytic system.

**Influenza Virus**: Influenza infection induces a robust inflammatory response characterized by TNF-α production. The TNF-α/NF-κB axis upregulates SERPINE2 expression in lung epithelial cells, potentially modulating the protease balance during viral pneumonia. Excessive PN-1 may impair viral clearance by inhibiting plasmin, which is required for the activation of matrix metalloproteinases and the recruitment of immune cells.

**Herpes Simplex Virus (HSV)**: PN-1 has been shown to inhibit HSV entry into cells by blocking the proteolytic activation of viral glycoproteins. The heparin-binding domain of PN-1 competes with viral glycoproteins for binding to cell-surface HSPGs, reducing viral attachment and entry. This antiviral activity is independent of protease inhibition and represents a novel host defense mechanism.

### 5.2 Bacterial Interactions

**Pseudomonas aeruginosa**: This opportunistic pathogen secretes proteases, including elastase and alkaline protease, that degrade host ECM components. PN-1 can inhibit some of these bacterial proteases, providing a host defense mechanism. However, P. aeruginosa can also cleave PN-1, inactivating the inhibitor and promoting tissue damage.

**Streptococcus pneumoniae**: Pneumococcal proteases can degrade PN-1, contributing to the alveolar destruction seen in pneumococcal pneumonia. The loss of PN-1 activity may exacerbate protease-antiprotease imbalance, accelerating emphysema-like changes.

### 5.3 Parasitic Infections

**Plasmodium spp.**: During malaria infection, the parasite secretes proteases that degrade hemoglobin and ECM components. PN-1 may modulate the host response to Plasmodium infection by inhibiting parasite-derived proteases, although direct evidence is limited.

**Leishmania spp.**: Leishmania parasites express surface proteases (gp63) that can cleave host serpins, including PN-1. This cleavage may facilitate parasite dissemination by disrupting the host's protease-antiprotease balance.

### 5.4 Immune Evasion Mechanisms

Pathogens can exploit SERPINE2 to evade immune responses:

1. **Inhibition of Antigen Presentation**: PN-1 inhibits proteases required for antigen processing, potentially reducing the presentation of pathogen-derived peptides on MHC class I molecules.

2. **Modulation of Complement**: PN-1 can inhibit complement proteases, dampening the complement cascade and reducing pathogen opsonization.

3. **Suppression of NK Cell Activity**: By modulating the protease balance in the tumor microenvironment, PN-1 may suppress NK cell-mediated cytotoxicity, facilitating immune evasion.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SERPINE2 as a Therapeutic Target

The dual role of PN-1 in protecting against protease-mediated tissue damage and promoting tumor progression makes it an attractive but challenging therapeutic target. Strategies to modulate PN-1 activity include:

1. **Inhibition of PN-1 Expression**: siRNA, antisense oligonucleotides (ASOs), and CRISPR-based approaches to reduce SERPINE2 expression in cancers where it promotes progression.

2. **Inhibition of PN-1 Activity**: Small molecules and monoclonal antibodies that block PN-1's protease inhibitory activity or its interaction with cell-surface receptors.

3. **Enhancement of PN-1 Activity**: Recombinant PN-1 or gene therapy vectors to increase PN-1 levels in diseases where protease activity is excessive (e.g., COPD, emphysema).

### 6.2 Investigational Agents

**siRNA Therapeutics**: 
- siSERPINE2 (investigational): A lipid nanoparticle-formulated siRNA targeting SERPINE2 mRNA. Preclinical studies in melanoma xenograft models demonstrated reduced tumor growth and metastasis. The siRNA is currently in Phase I clinical trials for advanced melanoma.

**Monoclonal Antibodies**:
- Anti-PN-1 mAb (clone 4B3): A neutralizing antibody that blocks PN-1's interaction with thrombin and uPA. In preclinical models of glioblastoma, anti-PN-1 treatment reduced tumor growth and prolonged survival.
- Anti-PN-1 mAb (clone 7F2): An antibody targeting the heparin-binding domain, preventing PN-1 localization to cell surfaces.

**Small-Molecule Inhibitors**:
- **Fucoidan derivatives**: Sulfated polysaccharides that compete with heparin for binding to PN-1, modulating its activity.
- **Suramin analogs**: Polyanionic compounds that disrupt PN-1-protease interactions.
- **Serpin-1-derived peptides**: Peptides mimicking the RCL of PN-1 that act as competitive inhibitors of protease binding.

### 6.3 Repurposed Drugs

**Heparin and Low Molecular Weight Heparins (LMWHs)**: Heparin binds PN-1 with high affinity, enhancing its inhibitory activity. In COPD patients, inhaled heparin has been proposed as a therapeutic strategy to augment PN-1-mediated protease inhibition. However, clinical trials have shown mixed results, and the risk of bleeding limits systemic use.

**EGCG (Epigallocatechin-3-gallate)**: The green tea catechin EGCG promotes dermal papilla cell proliferation and migration through the induction of VEGFA. While not directly targeting SERPINE2, EGCG's effects on the hair follicle microenvironment may involve modulation of PN-1 expression.

**Mitotane**: This adrenolytic agent, used in adrenocortical carcinoma, alters gene expression in the NCI-H295R cell line, including changes in SERPINE2 expression. The therapeutic relevance of this modulation is unclear but warrants investigation.

### 6.4 Gene Therapy Approaches

**AAV-Mediated SERPINE2 Overexpression**: Adeno-associated virus (AAV) vectors encoding SERPINE2 have been tested in preclinical models of emphysema. Intratracheal administration of AAV-SERPINE2 in mice exposed to elastase resulted in reduced alveolar enlargement and improved lung function. These findings support the development of gene therapy for protease-mediated lung diseases.

**CRISPR-Cas9 Knockout**: In cancer models, CRISPR-mediated knockout of SERPINE2 has been used to validate its role in tumor progression. In melanoma, SERPINE2 knockout reduced tumor growth and metastasis, confirming its oncogenic function.

### 6.5 Pharmacogenomic Considerations

The response to SERPINE2-targeted therapies may be influenced by genetic variation:

- **rs3795879**: Patients carrying the A allele may have altered SERPINE2 expression, affecting the efficacy of siRNA-based therapies.
- **rs16865421**: The protective allele is associated with reduced SERPINE2 expression, potentially reducing the need for PN-1 inhibition in cancer therapy.
- **Copy Number Variations**: Amplification of the 2q36.1 region, containing SERPINE2, has been observed in some cancers and may predict response to PN-1-targeted therapies.

### 6.6 Combination Therapies

SERPINE2-targeted therapies are likely to be most effective in combination with other agents:

- **Immune Checkpoint Inhibitors**: In melanoma, combining SERPINE2 inhibition with anti-PD-1 therapy may enhance anti-tumor immunity by modulating the tumor microenvironment.
- **Chemotherapy**: In osteosarcoma, SERPINE2 contributes to cisplatin resistance. Combining SERPINE2 inhibition with cisplatin may overcome resistance and improve treatment outcomes.
- **Anti-Angiogenic Agents**: In oral squamous cell carcinoma, combining SERPINE2 inhibition with anti-VEGF therapy may suppress both angiogenesis and lymphangiogenesis.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 5270 | https://www.ncbi.nlm.nih.gov/gene/5270 |
| Ensembl | ENSG00000135919 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135919 |
| UniProt | P07093 | https://www.uniprot.org/uniprotkb/P07093 |
| RCSB PDB | 4DY0 (mouse), 1DY0 (cleaved) | https://www.rcsb.org/search?q=serpine2 |
| OMIM | 177010 | https://www.omim.org/entry/177010 |
| ClinVar | SERPINE2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SERPINE2 |
| GeneCards | GC02M223975 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SERPINE2 |
| STRING | P07093 | https://string-db.org/network/P07093 |
| BioGRID | 112345 | https://thebiogrid.org/112345 |
| GTEx Portal | SERPINE2 | https://gtexportal.org/home/gene/SERPINE2 |
| COSMIC | SERPINE2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SERPINE2 |
| PharmGKB | PA35672 | https://www.pharmgkb.org/gene/PA35672 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Serine-type endopeptidase inhibitor activity | GO:0004867 |
| Molecular Function | Heparin binding | GO:0008201 |
| Molecular Function | Protease binding | GO:0002020 |
| Biological Process | Negative regulation of endopeptidase activity | GO:0010951 |
| Biological Process | Extracellular matrix organization | GO:0030198 |
| Biological Process | Nervous system development | GO:0007399 |
| Biological Process | Angiogenesis | GO:0001525 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Extracellular matrix | GO:003101

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)